MRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines.

ABSTRACT: Causing approximately a billion infections globally annually, the influenza virus represents one of the globe's greatest viral threats. While current vaccines protect against severe outcomes, especially for vulnerable populations, they offer limited prevention of infection and disease. Novel platforms like mRNA enable rapid updates, multivalent designs, and potentially stronger and more effective immune responses. To assess immune responses to mRNA vaccination, a system serology approach compared humoral profiles between recipients of investigational seasonal influenza mRNA-1010 vaccine and adjuvanted inactivated influenza vaccine (ClinicalTrials.gov Identifier: NCT05397223 ; registered May 31, 2022). Both platforms induced similar overall HA-specific antibody subclass and isotype response

SUBMITTER: Kaplonek P 

PROVIDER: S-EPMC12823603 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature